Medical Marijuana Dispensaries in European Union: Market Size, Businesses & Forecast 2026

The medical marijuana industry in the European Union consists of the importation, prescription distribution, and dispensing of pharmaceutical-grade cannabis products strictly through licensed pharmacies. Due to strict EU Good Manufacturing Practices (EU-GMP) and a lack of US-style retail dispensaries, distribution is fully integrated into the existing clinical healthcare infrastructure. Driven by major regulatory updates, such as Spain's Royal Decree 903/2025 and Germany's landmark 2024 Cannabis Act, patient registries are scaling rapidly. Germany remains the largest single market, with domestic sales of medical cannabis under its specialized framework reaching an official figure of EUR 485

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Medical Marijuana Dispensaries in European Union industry cover?

In the European Union, there is no legal concept of an independent retail 'marijuana dispensary' as seen in North America. Instead, medical cannabis is defined as a highly regulated pharmaceutical preparation or magistral formula that must be dispensed exclusively by registered pharmacists. All products, ranging from standardized oral solutions and oils to dried flower, must adhere to strict European Union Good Manufacturing Practices (EU-GMP) and are distributed via specialized clinical channels under medical supervision.

• •Under NACE Rev. 2, the dispensing of medical cannabis falls under code 47.73 (Dispensing chemist in specialized stores / Pharmacies).
• •The sector explicitly excludes general wellness CBD products, focusing solely on high-THC or standardized CBD/THC medicines prescribed by authorized physicians.
• •Medical cannabis preparations are treated as Rx-only narcotic or standardized controlled substances depending on the member state's specific laws.

Who operates in the industry and how is it structured?

The market is heavily centralized around national healthcare infrastructures, requiring partnerships between domestic pharmaceutical distributors, importing entities, and community or hospital pharmacies. Because direct-to-consumer commercial storefronts are illegal, European operators function as vertically integrated cultivators, clinical trial facilitators, or specialized wholesalers. Highly regulated supply chains ensure that importing countries, like Germany and Italy, source their products from EU-GMP-certified facilities in nations like Portugal, Spain, and Canada.

• •In Italy, the Ministry of Defence operates domestic cultivation directly via the Military Pharmaceutical Chemical Stabilisation facility in Florence to maintain supply security.
• •Spain's medical program restricts dispensing strictly to hospital-based pharmacies, completely excluding any retail storefronts.
• •The German market utilizes specialized domestic wholesalers who act as intermediaries, repackaging and distributing raw flowers and standardized extracts directly to more than 19,000 community pharmacies.

What drives demand in the industry?

Demand is primarily driven by expanding clinical indications, increasing physician familiarity, and the progressive integration of cannabis medicines into public healthcare reimbursement programs. Chronic neuropathic pain, multiple sclerosis-related spasticity, oncology palliative care, and chemotherapy-induced nausea represent the leading medical justifications for prescriptions. As statutory health insurance providers expand their coverage criteria, the out-of-pocket cost burden on patients is declining, leading to substantial registry growth.

• •In Germany, statutory health insurance (GKV) covers a significant portion of medical cannabis prescriptions under reformed social security codes.
• •France's permanent medical cannabis framework, codified in 2024 after a multi-year pilot program, targets approximately 70,000 patients with refractory conditions.
• •The United Kingdom's private medical cannabis patient base grew to approximately 100,000 active prescriptions by 2025, driven by private specialist clinics.

Who are the notable companies in the industry?

The competitive landscape features a mix of multinational operators with localized EU-GMP infrastructure and specialized European pharmaceutical firms. Regulatory first-movers command significant advantages, particularly those with established manufacturing, testing, and registration operations inside the EU. Competition is increasingly focused on developing proprietary, standardized drug formulations, certified medical delivery devices, and securing long-term supply agreements with state-run regulatory bodies.

• •Curaleaf Holdings, Inc. (operating locally as Curaleaf International) became the first company to register standardized oil-based preparations (CAN-1 and CAN-2) in Spain under Royal Decree 903/2025 in July 2026.
• •Tilray Brands, Inc. operates a major EU-GMP certified cultivation and manufacturing facility in Cantanhede, Portugal, serving as a primary export hub for EU member states.
• •Aurora Cannabis Inc. maintains a strong European presence through its German subsidiary, Aurora Deutschland GmbH, which holds domestic cultivation contracts issued by the Federal Institute for Drugs and Medical Devices (BfArM).
• •Demecan (Deutsche Medizinalcannabis GmbH) is a prominent privately-held, vertically integrated German pharmaceutical company licensed to cultivate and distribute medical cannabis domestically.

What are the recent trends and outlook?

The European medical cannabis sector is undergoing rapid evolution away from raw flower inhalation toward highly standardized, pharmaceutical-grade delivery mechanisms. This shift is supported by the introduction of CE-certified medical devices and liquid inhalation systems that ensure precise, metered dosage. Over the medium term, harmonized European regulatory standards are expected to lower cross-border barriers, facilitating frictionless trade between certified manufacturing facilities across the Schengen Area.

• •Curaleaf International secured an EU Class IIa medical device certification in late 2025 for its proprietary handheld liquid inhalation device designed for standardized dosing.
• •Spain's Agency of Medicines and Medical Devices (AEMPS) has moved to exclude raw cannabis flower from its national formulary in favor of standardized oral solutions.
• •Germany's 2024 Cannabis Act formally de-scheduled medical cannabis from the Narcotics Act, dramatically streamlining the prescription writing process for general practitioners.

How is the industry regulated?

Compliance within the European Union is governed by a complex, non-harmonized patchwork of national laws operating within a unified EU-GMP framework. Under international treaties, such as the UN Single Convention on Narcotic Drugs, governments must establish specialized agencies to control, purchase, and license all medical cannabis activities. Companies must strictly adhere to Good Agricultural and Collection Practices (GACP) for raw cultivation, followed by EU-GMP certification for all manufacturing and distribution operations.

• •In Germany, the Federal Institute for Drugs and Medical Devices (BfArM) oversees the Cannabis Agency, which controls domestic production quotas.
• •Spain's medical cannabis framework is governed by Royal Decree 903/2025, which sets strict quality parameters for magistral formulas registered with AEMPS.
• •The French National Agency for the Safety of Medicines and Health Products (ANSM) regulates the national supplier pool, requiring stringent clinical tracking for all authorized patients.

Government, statistical and trade sources used for this Claight analysis.

• German Federal Institute for Drugs and Medical Devices (BfArM) 2024 ·
• Spanish Agency of Medicines and Medical Devices (AEMPS) 2025-2026 ·
• French National Agency for the Safety of Medicines and Health Products (ANSM) 2024 ·
• Eurostat NACE Rev. 2 Classification Database 2024 ·
• European Medicinal Cannabis Association (EUMCA) 2025